HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brooks, D J Articles by Sagar, H Search for Related Content PubMed PubMed Citation Articles by Brooks, D J Articles by Sagar, H

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study

¹ Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, London, UK
² Department of Clinical Neurology, Royal Hallamshire Hospital, University of Sheffield, Sheffield, UK

Correspondence to:
Correspondence to:
Professor David J Brooks, MRC Cyclotron Building, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK;
david.brooks{at}csc.mrc.ac.uk

Methods: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose.

Results: The primary efficacy variable for fluctuating patients—the proportion of daily ON time—showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients.

Conclusions: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson’s disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.

Keywords: Parkinson’s disease; levodopa; COMT inhibition; entacapone

This article has been cited by other articles:

				C. H. Waters and J. J. Chen Pharmacologic Options for Treatment of Levodopa-Associated ``Wearing Off'' Journal of Pharmacy Practice, August 1, 2008; 21(4): 254 - 261. [Abstract] [PDF]

				J. Hudry, J. O Rinne, T. Keranen, L. Eckert, and J. M Cochran Cost-Utility Model of Rasagiline in the Treatment of Advanced Parkinson's Disease in Finland Ann. Pharmacother., April 1, 2006; 40(4): 651 - 657. [Abstract] [Full Text] [PDF]

				B R Thanvi and T C N Lo Long term motor complications of levodopa: clinical features, mechanisms, and management strategies Postgrad. Med. J., August 1, 2004; 80(946): 452 - 458. [Abstract] [Full Text] [PDF]

				K Wheatley, N Ives, R Gray, and C Clarke Role of entacapone in later Parkinson's disease not yet established J. Neurol. Neurosurg. Psychiatry, July 1, 2004; 75(7): 1081 - 1081. [Full Text] [PDF]

				W. Poewe The role of COMT inhibition in the treatment of Parkinson's disease Neurology, January 13, 2004; 62(90011): S31 - 38. [Abstract] [Full Text]